ENTPD1 and neoplasm: It was revealed that the eATP-P2X7-ASC-NALP3 inflammatory body-IL18 pathway plays an important role in blocking the anti-tumor activity mediated by the CD39 enzyme, rather than simply reducing adenosine as the mechanism [1].